Los Angeles, CANCT07276373Now EnrollingIRB Ready

Neoplasms Clinical Trial in Los Angeles, CA

Access cutting-edge neoplasms treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.

Sponsored by Corcept Therapeutics

Quick Self-Assessment

See if you qualify for this Los Angeles location

Preparing your pre-screening questions…

Expert Care in Los Angeles

Access neoplasms specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related neoplasms treatment provided free

Apply for This Los Angeles Location

Check if you qualify for this neoplasms clinical trial in Los Angeles, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Los Angeles

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Los Angeles site if eligible
  4. 4Begin participation

About This Neoplasms Study in Los Angeles

This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.

Sponsor: Corcept Therapeutics

Who Can Participate

Inclusion Criteria

Signed and dated institutional review board (IRB)/ independent ethics committee (IEC)-approved informed consent form (ICF)
Has solid malignancies that have received all available standard therapies for the specific tumor type or for which no standard therapy exists, unless patient is intolerant of treatment
Has a life expectancy of ≥ 3 months
Has evaluable disease based on RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Has adequate organ function
Negative serum or urine pregnancy test for female patients of childbearing potential
Agreement to use appropriate precautions to avoid pregnancy, unless the patient and/or their sole sexual partner is permanently sterilized

Exclusion Criteria

Past or current immune-related adverse events (irAEs) due to anti-programmed cell death protein 1 ligand 1 (PD\[L\]1) therapy that meet any of the following criteria:
Resulted in discontinuation of anti-PD(L)1 therapy
Medical history of an autoimmune or inflammatory disease requiring immunosuppressive therapy
Medical history of adrenal insufficiency
Has had any major surgery within 4 weeks prior to the first dose of study treatment
Concurrent treatment with mifepristone or another glucocorticoid receptor (GR) modulator
Unable to swallow, retain, or absorb oral medication
Concurrent participation in another interventional clinical trial
Has toxicities due to prior therapies that are reversible and have not resolved
Requirement for treatment with prohibited medications, including but not limited to systemic corticosteroids and cytochrome P450(CYP)3A inducers or inhibitors
Has a known history of severe hypersensitivity to any of the study drugs, or other human/humanized monoclonal antibodies
Pregnant or lactating patients or female patients expecting to conceive children within the projected duration of the trial
Has clinically significant uncontrolled condition(s) which, in the opinion of the Investigator, may confound the results of the trial or interfere with the patient's safety or participation
Known psychiatric disorder that would interfere with trial compliance
Has infection with HIV, hepatitis C virus, or hepatitis B virus
Has untreated parenchymal brain metastasis or has uncontrolled central nervous system metastases
Has a history of another malignancy within 2 years prior to study treatment, unless cured
Has received prior autologous or allogeneic organ or tissue transplantation
A QTcF interval \>450 msec, a family history of long QT syndrome or unexplained sudden death at young age, or a requirement for use of medication that may prolong the QTc interval

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT07276373) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Neoplasms Treatment Options in Los Angeles, CA

If you're searching for neoplasms treatment options in Los Angeles, CA, this clinical trial (NCT07276373) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced neoplasms specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all neoplasms clinical trials near you to find additional studies recruiting in your area.

More Myeloproliferative Neoplasms Trials in Los Angeles, CA

See all myeloproliferative neoplasms clinical trials recruiting in Los Angeles — not just this study.

Browse Myeloproliferative Neoplasms Trials in Los Angeles →

Browse More Trials by Condition

Myeloproliferative Neoplasms TrialsMultiple Sclerosis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Los Angeles?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Los Angeles, CA